Toni Choueiri, MD· @DrChoueiri · X·· 1 天前评分70
正文 · 原文
Another positive Ph.III in NSCLC! #DrShunLu presents SAFFRON: osimertinib + savolitinib vs platinum/pemetrexed after osimertinib in EGFRm/MET+ disease. PFS 7.6 vs 5.4 mo (HR 0.55; p<0.001). OS 17.8 vs 12.9 mo (HR 0.68; p=0.010).
#ESMO26 #LungCancer @myESMO @OncoAlert
61 浏览 · 1 赞 · 1 转发 · 0 回复
来源：Toni Choueiri, MD · x.com